These results provide evidence to support the idea that biogenic aldehydes such as DOPAL interact with human wild‐type alpha‐synuclein, directly or indirectly, in vivo to exacerbate locomotor deficits in Parkinson's disease. The gene discussed is SNCA; the disease is Parkinson disease.